Literature DB >> 28846481

Effectiveness of Combined Tear Film Therapy in Patients with Evaporative Dry Eye with Short Tear Film Breakup Time.

Yung Hui Kim1, Yeon Soo Kang1, Hyo Seok Lee1, Won Choi1, In Cheon You2, Kyung Chul Yoon1.   

Abstract

PURPOSE: The aim of this study was to evaluate the effectiveness of combined tear film therapy targeted to aqueous, mucin, and lipid layers in patients with refractory evaporative dry eye (EDE) with short tear film breakup time (TBUT).
METHODS: The patients who had EDE with short TBUT and severe symptoms refractory to artificial tears were treated with hyaluronic acid (HA) 0.15% and diquafosol tetrasodium (DQS) 3% (Group 1), HA and carbomer-based lipid-containing eyedrops (Liposic EDO Gel, LPO) (Group 2), or HA, DQS, and LPO (Group 3). Ocular Surface Disease Index (OSDI) score, visual analog scale (VAS) symptom score, TBUT, Schirmer score, and corneal and conjunctival staining scores were evaluated, and noninvasive tear film breakup time (NIBUT) and tear meniscus height were measured using Keratograph® 5 M before and 1 and 3 months after treatment.
RESULTS: OSDI scores, VAS scores, TBUT, and NIBUT were improved at 1 and 3 months after treatment in all groups (all P < 0.05). At each follow-up visit, the total OSDI, OSDI symptom, and all VAS scores were significantly lower in group 3 compared with groups 1 and 2 (all P < 0.05). In addition, TBUT and NIBUT were significantly higher in group 3 compared with groups 1 and 2 (all P < 0.05). No significant adverse effects were noted in the groups during treatment.
CONCLUSIONS: Mucin or lipid-targeting agents combined with aqueous supplements in patients with refractory EDE with short TBUT might improve subjective symptoms and TBUT. Of this, targeting whole tear film layers was most effective in improving ocular symptoms and tear film quality.

Entities:  

Keywords:  carbomer-based; combined tear film therapy; diquas; evaporative; liposic EDO; short tear film breakup time

Mesh:

Substances:

Year:  2017        PMID: 28846481     DOI: 10.1089/jop.2017.0019

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  6 in total

1.  Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction.

Authors:  José-María Sánchez-González; Concepción De-Hita-Cantalejo; María Carmen Sánchez-González
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

2.  Disease aetiology-based design of multifunctional microemulsion eye drops for moderate or severe dry eye: a randomized, quadruple-masked and active-controlled clinical trial.

Authors:  Jarmo Laihia; Riikka Järvinen; Edward Wylęgała; Kai Kaarniranta
Journal:  Acta Ophthalmol       Date:  2019-10-03       Impact factor: 3.761

Review 3.  Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.

Authors:  Yu-Kai Kuo; I-Chan Lin; Li-Nien Chien; Tzu-Yu Lin; Ying-Ting How; Ko-Hua Chen; Gregory J Dusting; Ching-Li Tseng
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

4.  Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use.

Authors:  Pedro Molina-Solana; Francisco de Borja Domínguez-Serrano; Antonio Manuel Garrido-Hermosilla; Jesús Montero-Iruzubieta; Ana Fernández-Palacín; Enrique Rodríguez-de-la-Rúa-Franch; Manuel Caro-Magdaleno
Journal:  Clin Ophthalmol       Date:  2020-04-28

5.  Short tear film breakup time-type of dry eye in India.

Authors:  Samrat Chatterjee; Deepshikha Agrawal
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

6.  Efficacy of eye drops containing crosslinked hyaluronic acid and CoQ10 in restoring ocular health exposed to chlorinated water.

Authors:  Costanza Tredici; Romina Fasciani; Antonio Villano; Gloria Gambini; Aldo Caporossi
Journal:  Eur J Ophthalmol       Date:  2020-02-16       Impact factor: 2.597

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.